stockrow
Monday 9 November 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMRAlamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Revenue
- +68.5%
- EPS
- +72.0%
- Free cash flow
- +1.07%
Quarter to September 2026, against a year earlier
28.05
1.14
+4.24%
Follow ALMR
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
3.09 | 3.09 |
Altman Z″-Score (non-manufacturers) |
(2.67) | (1.80) |
P/FCF ratio |
0.00 | 0.00 |
Beneish M-Score |
(0.82) | — |
P/Operating CF |
(13.26) | (13.26) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
3.21 | 3.21 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(4.60) | (4.60) |
EV/FCF |
(4.22) | (4.22) |
Quick Ratio |
1.80 | 5.20 |
Current Ratio |
3.99 | 6.43 |
Net Debt/EBITDA |
0.74 | 1.65 |
Debt/Assets |
7.01% | 0.00% |
Debt/Equity |
(0.06) | 0.00 |
Asset Turnover |
0.51 | 0.00 |
Operating CF/Net income |
1.80 | 1.19 |
Capex/Depreciation |
(1.37) | (2.13) |
Interest Coverage |
(78.14) | (23.85) |
| 20.40% | 0.00% | |
| (20.60%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(36.60%) | (47.39%) |
Average Days of Receivables |
62.72 | 96.51 |
Research and Development Expense of Revenue |
50.49% | 156.05% |
Selling, General and Administrative Expense of Revenue |
47.93% | 75.34% |
Intangible Assets out of Total Assets |
0.01 | 0.01 |
Share Based Compensation of Revenue |
3.87% | 3.47% |
Graham Net Nets |
(0.83) | (0.83) |
Graham Number |
28.28 | 0.00 |
Earnings Yield |
(16.55%) | (16.55%) |
Free Cash Flow Yield |
(24.58%) | (24.58%) |
Revenue per Share |
6.43 | 2.39 |
Operating CF per Share |
(4.64) | (5.25) |
Capex per Share |
(0.47) | (0.28) |
Free Cash Flow per Share |
(5.11) | (5.53) |
Cash per Share |
2.60 | 7.57 |
Shareholders Equity per Share |
(13.76) | (12.68) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(13.76) | (12.68) |
Free Cash Flow |
(58.98) | (58.16) |
Working Capital |
70.98 | 90.11 |
Capital Expenditures |
(5.37) | (2.95) |
Net Current Asset Value |
(204.24) | (176.22) |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.07 | 0.12 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.37 | 0.18 |
Cash ROIC |
49.50% | 108.12% |
Accounts Receivable Turnover |
7.65 | 0.00 |
Accounts Payable Turnover |
5.39 | 0.00 |
Inventory Turnover |
1.23 | 0.00 |
Average Days of Payables |
65.93 | 136.57 |
Days of Inventory on Hand |
432.10 | 318.05 |
Average Receivables |
9.70 | — |
Average Payables |
6.03 | — |
Average Inventory |
26.45 | — |
Average Assets |
144.75 | — |
Average Common Equity |
(146.18) | — |
Columns are period end dates · fundamentals updated 6 Nov 2026